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Renal anemia is a major complication in chronic kidney disease (CKD). Iron 
supplementation, as well as erythropoiesis-stimulating agents, are widely used for 
treatment of renal anemia. However, excess iron causes oxidative stress via the Fenton 
reaction, and iron supplementation might damage remnant renal function including 
erythropoietin (EPO) production in CKD. EPO gene expression was suppressed in 
mice following direct iron treatment. Hypoxia-inducible factor-2 alpha (HIF-2α), a 
positive regulator of the EPO gene, was also diminished in the kidney of mice 
following iron treatment. Anemia-induced increase in EPO and HIF-2α expression was 
also inhibited by iron-treatment. In in vitro experiments using EPO-producing HepG2 
cells, iron stimulation reduced the expression of the EPO gene, as well as HIF-2α. 
Moreover, iron treatment augmented oxidative stress, and iron-induced reduction of 
EPO and HIF-2α expression was restored by tempol, an anti-oxidant compound. 
HIF-2α interaction with the EPO promoter was inhibited by iron treatment, and was 
restored by tempol. These findings suggested that iron supplementation reduced EPO 





 The incidence of chronic kidney disease (CKD) has increased worldwide, and 
CKD worsens morbidity and mortality in the general population1, 2. Additionally, the 
progression of CKD results in end-stage renal failure, which requires treatment by 
hemodialysis or renal transplantation. In addition, a variety of complications arises 
during the course of CKD. Cardiovascular disease, a major complication of CKD, also 
leads to worse outcomes in CKD patients3. Renal anemia is commonly seen in 
individuals with CKD due to insufficient erythropoietin (EPO) production within the 
diseased kidney4, 5. Therefore, patients with end stage renal disease receive 
erythropoiesis-stimulating agent (ESA) for treatment of renal anemia. 
 Iron supplementation, in addition to ESA, is often used for treatment of renal 
anemia 6. However, patients with CKD often show functional iron deficiency, rather 
than absolute iron deficiency, characterized by impaired iron release from body iron 
stores 7. Disturbance of iron utilization in CKD occurs due to ferroportin (an cellular 
iron exporter) degradation resulting from increased hepcidin production8, 9. Hepcidin is 
a positively controlled by iron stores10. Therefore, iron treatment further exacerbates 
impaired iron utilization via hepcidin elevation and result in over accumulation of 
disused iron in organs of CKD individuals. Actually, adverse effects of iron 
supplementation on organs have been directly observed in several studies. Iron sucrose 
treatment exacerbates endothelial dysfunction in healthy subjects11 and atherosclerotic 
change through enhancement of oxidative stress in a CKD mouse model12. Intravenous 
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iron also causes oxidative stress and transient proteinuria, tubular damage and 
inflammatory cytokine production in patients with CKD13, 14. Thus, parenteral iron 
supplementation might aggravate and cause complications in CKD through oxidative 
stress production. Furthermore, iron might exacerbate erythropoietin production 
consequent to remnant kidney injury, however, the effect of iron on EPO regulation has 
not been elucidated.  
 Here, we demonstrate that saccharated ferric oxide (SFO) reduced renal EPO 
expression through iron-induced oxidative stress production dependent inactivation of 
hypoxia-inducible factor-2α. Our findings suggest that therapeutic iron 
supplementation has a harmful effect on EPO regulation in remnant kidney function, 
causing a vicious cycle of CKD progression.  
Materials and Methods 
Materials 
We purchased saccharated ferric oxide (SFO), cobalt chloride (CoCl2), tempol, 
and dimethyloxallyl glycine (DMOG) from Nichi-Iko Pharmaceutical Co., Ltd 
(Toyama, Japan), Wako Pure Chemical Industries, Ltd. (Osaka, Japan), Sigma-Aldrich 
(St. Louis, MO, USA), and Cayman Chemical Company (Michigan, USA), 
respectively. The following commercially available antibodies were used: anti-HIF-2α 
(R&D Systems, Inc. Minneapolis, MN, USA); anti-HIF-1α (Cayman Chemical 
Company, Ann Arbor, MI, USA); anti-PDGF-Rβ (Cell Signaling Technology, Beverly, 
MA, USA); anti-α-SMA (Sigma-Aldrich, St. Louis, MO, USA); anti-Lotus 
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Tetragonolobus Lectin (VECTOR Laboratories, Burlingame, CA, USA); E-cadherin 
(Cell Signaling Technology Japan, K.K., Tokyo, Japan); anti-α-tubulin, as a loading 
control, from Calbiochem (San Diego, CA, USA).  
Animal preparation and procedure  
All experimental procedures were performed in accordance with the 
guidelines of the Animal Research Committee of Tokushima University Graduate 
School, and protocols were approved by the Institutional Review Board for animal 
protection. Eight-week-old C57/BL6J mice were obtained from Nippon CLEA (Tokyo, 
Japan) and they were maintained with free access to water and food (Type NMF; 
Oriental Yeast, Tokyo, Japan). The unilateral ureteral obstruction (UUO) procedure 
was previously described in detail15. Our mouse model of chronic iron treatment was 
produced as previously described12. Briefly, intraperitoneal SFO (2 mg in a volume of 
200 µl) ⋅25 g mouse−1) or the same volume of vehicle was administered for five 
consecutive days. Mice were sacrificed 24 h after the last iron treatment. Mice were 
killed with an intraperitoneal injection of over-dose pentobarbital, and the kidney was 
removed and stored at −80°C until use. 
Induction of anemia by phlebotomy 
Phlebotomy was performed for two consecutive days. Briefly, after anesthesia, 
approximately 400 µL blood was removed via retroorbital bleeding and was replaced 
by the same volume of sterile normal saline by a subcutaneous injection. Then, mice 
were administered the vehicle or SFO via an intraperitoneal injection and were placed 
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on a heating pad until full recovery. Mice were sacrificed 24 h after the last 
phlebotomy. 
Cell culture 
Although renal EPO-producing cells are suggested to be derived from tubular 
interstitial cells such as fibroblasts 16, 17 or pericytes18, there are no cell lines 
established. Therefore, HepG2 cells, a human hepatoma cell line, have been used as 
EPO-producing cells in in vitro experiments 19-21. Similarly, we used HepG2 cells to 
investigate the mechanism of iron on EPO regulation in this study. HepG2 cell was 
purchased from the Japanese Collection of Research Bioresources (Osaka, Japan). 
Cells were cultured in Dulbecco's Modified Eagle's Medium (DMEM) (Wako Pure 
Chemical Industries, Ltd., Osaka, Japan) according to the protocol. For each 
experiment, cells at passage 5–8 were used. Cells were grown to confluence then 
transferred to serum-free medium before the start of the experiments. In some 
experiments, cells were pretreated with 100 µM CoCl2, 200 µM DMOG, and 100 µM 
tempol for 1 h before stimulation with SFO. 
RNA extraction and evaluation of mRNA expression levels 
RNA extraction, cDNA synthesis, and quantitative RT-PCR methods have 
been previously described15. Briefly, tissues or cells were homogenized in RNAiso 
reagent (TAKARA Bio, Inc., Otsu, Japan). RNA extraction and cDNA synthesis were 
performed according to the manufacturer’s instructions (PrimeScript RT reagent Kit 
with gDNA Eraser (Perfect Real Time), TAKARA Bio, Inc.). Quantitative RT-PCR 
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was performed using the CFX Connect Real-Time PCR Detection System (BIO-RAD 
Laboratories Inc., Hercules, CA, USA) with THUNDERBIRD SYBR qPCR Mix 
(TOYOBO CO., LTD., Osaka, Japan). The expression levels of all target genes were 
normalized using 36B4 as an internal control15. The primer sets used are noted in Table 
1. 
Protein extraction and western blot analysis 
Protein preparation and western blotting were performed as previously 
described15. Briefly, the tissues or cell samples were homogenized and sonicated, and 
then proteins were extracted. Extracted proteins were boiled for 5 min in Laemmli 
sample buffer and separated using SDS-PAGE. Proteins were transferred to a 
polyvinylidene fluoride (PVDF) membrane and the membrane was blocked for 1 h at 
room temperature. Next, the membrane was incubated individually with each primary 
antibody overnight at 4°C, followed by incubation for 1 h with the secondary antibody. 
Immunoreactive bands were detected using a chemiluminescence reagent and 
visualized by exposure onto an X-ray film or by C-DiGit chemiluminescent scanner 
(LI–COR C-DiGit Blot Scanner, Lincoln, Nebraska, USA). Densitometry of the 
visualized bands was quantified using Image J 1.38x software. 
Immunohistochemistry in the kidney 
Extracted kidney tissues were embedded in OCT compound (Tissue-Tek, 
SAKURA Finetek, Tokyo, Japan) and frozen in liquid nitrogen-cold isopentane. 
Samples were cut into 8-µm sections, dried, and fixed in 4% paraformaldehyde for 10 
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min. After blocking, the tissue sections were incubated with 1:100 dilution of primary 
antibody at 4°C overnight. Antibody distribution was visualized using 
immunofluorescence (Alexa fluor; Life Technology, Tokyo, Japan). Sections incubated 
without primary antibody were used as negative controls.  
Measurement of tissue iron content  
Tissue iron content was measured using an iron assay kit according to the 
manufacturer’s instructions (Metallo assay, Metallogenics Co., Ltd., Chiba, Japan) as 
described previously15, 22. Briefly, extracted kidney tissues were weighed and 
homogenized in cell lysis buffer. Non-centrifuged crude lysates were additionally 
sonicated, then added and mixed with 6 N hydrochloric acid to a final concentration of 
0.05 M at room temperature for 30 min. After centrifugation, supernatants were used 
for iron measurement. Tissue iron concentration was corrected using tissue weight and 
expressed as µg Fe·g-1 wet tissue. 
Cell viability assay 
Cell viability was accessed using CellTiter 96 AQueous nonradioactive cell 
proliferation assay kit (Promega KK, Tokyo, Japan)23. Briefly, HepG2 cells were 
seeded in 96-well plates at 1 × 104 cells per well and incubated for 24 h. Subsequently, 
various concentrations of SFO were added for 24 h and the impact of SFO on cell 
viability was assessed 1 h after the addition of MTS reagent by measuring absorbance 
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at 490 nm with a plate reader (iMARK microplate reader, BIO-RAD Laboratories Inc., 
Hercules, CA, USA). 
Detection of labile ferrous iron 
We used RhoNox-1 to detect intracellular labile ferrous iron. RhoNox-1 was 
kindly provided from Dr. Tasuku Hirayama and Prof. Hideko Nagasawa 24. In brief, an 
unfixed frozen section of the kidney was washed with Hank's Balanced Salt Solution 
(HBSS) 3 times and incubated with RhoNox-1 in HBSS (5 µM) in a dark, humidified 
container at room temperature for 30 min. After washing with HBSS 3 times, section 
was covered with a small drop of the mounting medium, and observed using 
fluorescence microscopy. In some experiments, frozen sections were fixed in 10% 
neutral formaldehyde for 1 min, washed with HBSS, and incubated with RhoNOX-125. 
Then, the sections were incubated with the primary antibody at 4°C overnight in a dark 
humidified container. Lectin or E-cadherin was used as a marker of the proximal or 
distal tubules, respectively. In HepG2 cells, cells were seeded in a 24-well culture plate 
or a black 96-well microplate. HepG2 was stimulated with SFO for 1 h and then loaded 
with 5 µM RhoNox-1 in HBSS at 37°C for 30 min. After washing, ferrous iron was 
observed using fluorescence microscopy or quantitatively measured at 530 and 575 nm 
for RhoNox-1 using a fluorescence microplate reader (Varilskan Flash, Thermo Fisher 
Scientific, Waltham, MA, USA). 
In situ oxidative stress detection in kidney tissue 
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Detection of superoxide production in the kidney was evaluated by 
dihydroethidium (DHE) staining method as described previously22. Briefly, non-fixed 
frozen tissue sections were incubated with DHE in PBS (10 µM) in a dark, humidified 
container at room temperature for 30 min and then observed using fluorescence 
microscopy.  
Intracellular reactive oxidative species detection 
Intracellular reactive oxidative species (ROS) were detected using 
2′,7′-Dichlorofluorescin diacetate (DCFH-DA) (Sigma-Aldrich, St. Louis, MO, USA). 
HepG2 was stimulated with SFO for 1h and then loaded with 10 µM DCFH-DA at 
37°C for 30 min. After washing, ROS production was observed using fluorescence 
microscopy or quantitatively measured at 488 and 532 nm for DCFH-DA using a 
microplate reader (FilterMax F3 Multi-Mode Microplate Readers, Molecular Devices, 
LLC., Sunnyvale, CA, USA).  
Chromatin immunoprecipitation 
Chromatin immunoprecipitation (ChIP) was performed to determine the 
interaction between the hypoxia-inducible factor-2 alpha HIF-2α protein and Epo-gene 
promoter containing the hypoxia response element (HRE). Briefly, HepG2 cells treated 
with vehicle or SFO, and with or without tempol were crosslinked with formaldehyde 
at final concentration of 1.0% for 10 min, then added to 2.5 mM glycine to stop the 
crosslinking reaction. Then, cells were collected, incubated with cell lysis buffer, and 
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the nuclear fraction was extracted. After sonication and centrifugation, the supernatant 
fraction was co-immunoprecipitated with HIF-2α protein using agarose beads (Protein 
A/G plus-Agarose, Santa Cruz Biotechnology, Inc.). The beads were washed and 
incubated at 65°C in elution buffer to reverse the cross-links. DNA was purified from 
the elution buffer and used for PCR. The primer sequence for the HRE-containing 
region of the human EPO promoter was used as shown previously26. The primer 
sequences, used to amplify the HRE-containing region of the human EPO promoter 
were as follows: EPO forward primer 5'- TCGTTTTCTGGGAACCTCCA-3', and 
EPO reverse primer 5'-GGAGC- CACCTTATTGACCAG-3'. 
Hypoxia-responsive element Luciferase Reporter Assay  
The hypoxia-responsive reporter vector was constructed using 3 tandem 
copies of the hypoxia-responsive element (HRE) from the human EPO gene subcloned 
into the secreted luciferase from the marine copepod Metridia longa transcription unit 
(pCre-MetLuc2-Reporter plasmid vector, Takara Bio Inc. Shiga, Japan). One-hundred 
ng pCre-MetLuc-HRE plasmid vector and 10 ng pSEAP2-Control plasmid vector 
(Takara Bio Inc.) were co-transfected in 1 × 104 HepG2 cells using Lipofectamine 
2000 (Thermo Fisher Scientific Inc.) in a 96-well culture plate. The transfected cells 
were exposed to the vehicle or SFO for 24 h and then the cell culture medium was 
harvested and both luciferase and alkaline phosphatase (ALP) activities were measured 
using Secreted Luciferase Reporter Assay (Takara Bio Inc.) and SEAP Reporter Gene 
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Assay (Sigma-Aldrich Japan K.K., Tokyo, Japan), respectively, according to the 
manufacturer’s instructions. To normalize the transfection efficiency, the RLU of the 
luciferase chemiluminescence unit was divided by that of the ALP chemiluminescence 
unit. 
Measurement of plasma EPO concentration 
 Plasma EPO concentration was determined by using an ELISA kit, according 
to the manufacturer’s instructions (Mouse Erythropoietin Quantikine ELISA Kit, R&D 
systems Inc., Minneapolis, MN, USA). 
Statistical analysis 
Data are presented as mean ± standard deviation (SD). An unpaired, 2-tailed 
Student’s t-test was used for comparison between the two groups. For comparisons 
between more than two groups, the statistical significance of each difference was 
evaluated by post-hoc test using Dunnett’s method or Tukey-Kramer’s method. 
Statistical significance was indicated by P < 0.05. 
Results 
EPO expression and iron content in the kidney with UUO surgery 
 EPO mRNA levels are drastically reduced in kidneys with UUO surgery17. 
Similarly, EPO mRNA expression was decreased in the kidney at 7 days after UUO 
surgery compared to sham-operation (Figure 1A). We have already demonstrated that 
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renal iron content was significantly augmented in UUO-induced fibrotic kidney in the 
previous study 15.  
EPO expression and iron content in the kidney of iron-treated mice 
To examine direct action of iron on EPO expression, we used mice with SFO 
treatment. Renal iron content was significantly increased in mice with SFO treatment 
for consecutive five days compared to vehicle-treated mice (vehicle; 12.0 ± 3.6 µg 
Fe·g-1 wet tissue, SFO; 20.8 ± 4.2 µg Fe·g-1 wet tissue, n=3, p<0.05). EPO mRNA 
expression was decreased in the kidney of SFO-treated mice compared to 
vehicle-treated mice (Figure 1D). Similarly, the plasma EPO concentration was also 
suppressed in SFO-treated mice (Table 4). There were no significant differences in 
hematological parameters of red blood cells between vehicle- and SFO-treated mice 
(Table 2). 
HIF-2α expression in the kidney with UUO and iron-treated mice 
  HIF-2α is an important regulator of EPO expression in the kidney27 and 
liver26. HIF-2α expression was diminished in the kidneys with UUO and iron treatment 
compared to the kidneys with sham- or vehicle-treatment (Figure 1C and F). These 
findings suggest that iron accumulation suppresses renal EPO expression through the 
inhibition of HIF-2α. In contrast, HIF-1α mRNA was not changed and HIF-1α protein 
was decreased in the kidney of UUO mice (Figure 1B and C), whereas HIF-1α mRNA 
 15 
 
was elevated and HIF-1α protein tended to decrease in the kidney of SFO-treated mice 
(Figure 1E and F). 
SFO action on transition of fibroblast to myofibroblast in kidneys 
EPO production occurs in fibroblasts, and loss of EPO production occurs 
during the transition of fibroblast to myofibroblast in the course of renal fibrosis 
progression16, 17. The fibroblast to myofibroblast transition plays an important role in 
the process of renal fibrosis28. Therefore, we checked whether iron was involved in the 
fibroblast to myofibroblast transition-dependent loss of EPO production. No apparent 
parenchymal damages were seen in the kidney of SFO-treated mice compared to 
vehicle-treated mice (Figure 2A). SFO treatment augmented the expression of 
PDGF-Rβ and α-SMA proteins in the kidney, compared to vehicle treatment (Figure 
2B and C). Immunohistochemical analysis showed that PDGF-Rβ expression was 
increased in the renal interstitium of SFO-treated kidneys. α-SMA expression also 
increased in the renal interstitium of SFO-treated kidneys. In contrast, it was almost 
completely localized in vessels in vehicle-treated kidneys. Moreover, PDGF-Rβ and 
α-SMA expression were colocalized in the renal interstitium of SFO-treated kidneys 
(Figure 2D). These results suggest that iron-induced EPO reduction occurs due to an 
induction of renal fibrotic change and the myofibroblast transition. 
The effect of SFO on EPO mRNA expression in HepG2 cells 
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First, we performed the MTS cell proliferation assay to determine the effect 
of SFO on the viability of HepG2 cells. SFO had no effect of cellular viability at 50, 
100, and 200 µg·ml-1 but significantly reduced cell viability at 1000 µg·ml-1. This result 
indicates that high concentrations of SFO are toxic for HepG2 cells (Figure 3A). 
Therefore, we used SFO at concentrations of 200 µg/ml and below in further studies. 
To examine the effect of SFO on EPO mRNA expression, we examined EPO mRNA 
expression after treatment with various concentration of SFO. As shown in Figure 3B, 
SFO significantly reduced EPO mRNA expression in a dose-dependent manner. 
HIF-2α mRNA and protein levels were also reduced by SFO treatment in HepG2 cells 
(Figure 3C and D). In contrast, the expression of HIF-1α at the mRNA and protein 
levels decreased in HepG2 cells (Figure 3C and D). The results of these in vitro 
experiments are consistent with in vivo results demonstrating the effect of SFO on EPO 
and HIF-2α expression in the kidney. 
The suppressive effects of SFO on CoCl2 or DMOG-induced EPO and HIF-2α 
upregulation 
We examined the effects of SFO on EPO and HIF-2α expression under hypoxic 
conditions, using cobalt chloride to mimic conditions of hypoxia induction. EPO 
mRNA and HIF-2α protein expression were increased by cobalt chloride treatment. 
The hypoxia-induced increases in EPO mRNA and HIF-2α protein expression were 
suppressed by combining SFO and cobalt chloride treatments (Figure 3E and F). 
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DMOG is a prolyl hydroxylase inhibitor drug, and is also used for induction of HIF 
expression. As observed with cobalt chloride, DMOG treatment increased EPO mRNA 
and HIF-2α protein expression, and these increases were inhibited by concomitant SFO 
treatment (Figure 3G and H). Cobalt- or DMOG-induced HIF-1α protein expression 
was also decreased by concomitant SFO treatment (Figure 3F and H). 
SFO treatment induced oxidative stress 
Excess iron causes oxidative stress by producing hydroxyl radicals via the 
Fenton reaction29. SFO treatment actually increased labile ferrous iron mainly in both 
the proximal and distal tubule of the kidney (Figure 2E and H), and HepG2 cells 
(Figure 4A), suggesting to iron-induced oxidative stress consequent to Fenton reaction. 
Here, we showed that SFO induced oxidative stress in the kidney (Figure 2F). 
SFO-induced oxidative stress seemed to be dominantly localized in the glomeruli and a 
part of the proximal tubule (Figure 2G). SFO-induced oxidative stress was also 
observed in HepG2 cells (Figure 4B), and it was diminished by the anti-oxidant 
compound, tempol (Figure 4C). Iron content was elevated with SFO-treatment, which 
did not change following tempol treatment (Vehicle; 424 ± 460 ng Fe·g-1protein, SFO; 
9297 ± 685 ng Fe·g-1protein, SFO+tempol; 9597 ± 880 ng Fe·g-1protein). The 
suppressive effects of SFO on EPO mRNA and HIF-2α protein expression, but not 
HIF-2α mRNA, were prevented by tempol treatment (Figure 4D-F). SFO-induced 
reduction in HIF-1α protein was restored by tempol treatment (Figure 4F). These 
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findings indicate that SFO-mediated suppression of EPO and HIF-2α expression occurs 
via SFO-induced oxidative stress. 
SFO suppressed the interaction between the HIF-2α protein and Epo-HRE containing 
promoter  
We performed ChIP to examine the interaction between the HIF-2α protein 
and Epo-HRE containing promoter region. As shown in Figure 4G, SFO treatment 
reduced HIF-2α binding to the Epo promoter. The suppressive action of SFO on the 
HIF-2α and Epo-gene promoter interaction was restored by tempol treatment. These 
results suggest that SFO-induced EPO down-regulation was due to the inactivation of 
HIF-2α binding to the Epo-HRE containing promoter region. 
The promoter activity of HRE was inhibited by SFO treatment in HepG2 cells 
We also examined the effect of SFO on HRE promoter activity by luciferase 
assay. As shown in Figure 4H, SFO diminished the promoter activity of HRE by 50%, 
indicating the inhibitory action of SFO on Epo through transcriptional inactivity of 
HIF. 
Effect of SFO on HIF-regulated genes 
 HIF is a well-known transcriptional regulator for many genes. In addition to 
Epo, we assessed several HIF-regulated genes, such as Vegf, Phd3, and PGK1. In the in 
vivo studies, SFO treatment elevated mRNA expression of these 3 genes (Figure 5A). 
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However, only Phd3 mRNA expression was augmented by SFO treatment in HepG2 
cells (Figure 5B). PHD3 plays a crucial role in the regulation of HIF-230, indicating the 
involvement of iron in HIF-2α regulation.  
Inhibitory effect of SFO on anemia-induced EPO upregulation  
Finally, we examined whether SFO treatment suppresses anemia-induced 
EPO upregulation by using mice with phlebotomy-induced anemia. 
Phlebotomy-induced anemia in mice, and no differences in hematological parameters 
were observed in these mice regardless of SFO treatment (Table 3). As shown in 
Figure 5C and Table 4, anemia induced an increase in renal Epo mRNA expression as 
well as plasma EPO concentration, were suppressed by SFO treatment. Moreover, 
anemia-induced HIF-2α expression was also inhibited in SFO-treated mice with 
phlebotomy (Figure 5D).  
Discussion 
 In CKD, patients with renal anemia are commonly administered parenteral 
iron supplementation. However, iron treatment itself has adverse effects on various 
tissues through iron-related oxidative stress production. In the present study, we found 
that parenteral iron treatment reduced EPO mRNA and HIF-2α protein expression in 
the mouse kidney. Notably, iron treatment augmented oxidative stress production in 
both in vivo and in vitro experiments, and tempol could restore iron-induced reduction 
of EPO and HIF-2α expression in HepG2 cells. Moreover, iron suppressed HIF-2α 
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binding to the Epo-HRE containing promoter, which was ameliorated by tempol. These 
results suggest that iron reduces EPO expression through HIF-2α inactivation via 
oxidative stress production. 
 Renal fibrosis is an important factor in the progression of CKD leading to 
end-stage renal disease31, and renal anemia, a complication of CKD, develops along 
with renal fibrosis. The primary cause of renal anemia is inadequate EPO production 
consequent to loss of renal-EPO-producing cells due to renal fibrosis16. The murine 
UUO model is widely recognized to induce renal fibrosis with reduced EPO 
expression. Renal EPO expression is drastically reduced at day 1 or later after UUO 
surgery17. In the same murine UUO model, excess iron accumulation is observed in 
UUO-induced fibrotic kidneys compared to those of sham-operated mice15. 
Additionally we confirmed reduced EPO expression in UUO fibrotic kidneys. 
Consistent with the association between renal fibrosis and iron accumulation, several 
studies have shown that iron content is increased in fibrotic kidneys of the angiotensin 
II-infused rat32, Dahl salt-sensitive rat33, and 5/6 nephrectomized rat34. We, and others, 
have shown the anti-fibrotic effect of tissue iron reduction using iron chelators or iron 
restriction chow on the kidney15, 33, 34. Here, direct SFO treatment diminished renal 
EPO expression in the kidney with increased iron content. Therefore, there is a close 




 The EPO gene promoter contains a hypoxia response element (HRE) region. 
HIF promotes EPO transcription through binding to HRE in the Epo-promoter26, 35. It 
has been shown that HIF-1 and HIF-2 transcriptionally regulate EPO expression. 
However, using renal specific HIF-2α knockout mice it has been demonstrated that 
renal EPO expression is predominantly regulated by HIF-2α and not by HIF-1α36. 
Using an siRNA approach in Hep3B cells, constituting a hepatoma cell line37, and mice 
with conditional hepatic HIF-2α deletion it has been shown that EPO gene induction is 
largely dependent on HIF-2, not HIF-1 in the liver26. Thus, HIF-2α is recognized as a 
key regulator of EPO expression in both the kidney and liver. 
In this study, SFO treatment reduced HIF-2α expression, and HIF-2α protein 
binding to the Epo-promoter region. Additionally, SFO-induced HIF-2α inactivation 
was ameliorated by the anti-oxidant compound, tempol, indicating the involvement of 
iron-mediated oxidative stress in HIF-2α regulation. HIFs are generally regulated by 
post-transcriptional mechanisms that determine the rate of HIF protein degradation38, 
and its binding ability39. Iron itself is shown to antagonize HIF-mediated induction of 
EPO gene expression induced by cobalt chloride40, and iron supplementation reduces 
HIF-1α expression levels even under normoxia in PC3 cells41. This is the first study to 
describe the association between iron and HIF-2α, and to suggest that the preventive 
action of iron on EPO expression is mediated through a HIF-2α-dependent signaling 
pathway. Prolyl hydroxylase domain (PHD) also plays a crucial role in regulating HIF 
protein stability, and PHD activity is stimulated by ferric iron, and suppressed by iron 
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chelation42. Correspondingly, DMOG, a PHD inhibitor, induced EPO expression, 
which was also attenuated by concomitant SFO treatment in HepG2 cells. In addition, 
PHD3 is known to be a regulator of HIF-230, and SFO increased Phd3 mRNA 
expression in both the kidney and HepG2 cells, indicating the involvement of 
iron-induced PHD3 upregulation in HIF-2α reduction. Therefore, SFO-mediated EPO 
reduction might be involved in the destabilization of HIF-2α protein via the restoration 
of DMOG-inhibited PHD activity.  In contrast to phd3 mRNA expression, mice with 
SFO treatment showed increased mRNA expression of Vegf and PGK1 and these genes 
were not changed in HepG2 cells with SFO treatment. The different expression of 
HIF-regulated genes induced by iron might be due to tissue or cell from different 
organ. 
Oxidative stress is proposed to participate in regulating the protein stability 
and transcriptional activity of HIF. H2O2 destabilizes HIFs protein under hypoxia43, 44. 
Oxidative stresses such as diamide, N-ethylmaleimide, and H2O2 also inhibit the DNA 
binding activity of HIF-139. H2O2 suppresses hypoxia-induced EPO production in 
HepG2 cells45, which might be due to oxidative stress-mediated HIF inactivation. 
Taken together, iron-induced oxidative stress could be responsible for protein 
stabilization and DNA binding activity of HIF. Moreover, tempol ameliorated 
SFO-induced inhibition of the HIF-2α–EPO signaling pathway without affecting 
intracellular iron content. Therefore, concomitant treatment of anti-oxidant drugs might 
be effective for reducing the oxidative stress induced by iron supplementation. 
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HIF proteins are involved in the post-transcriptional regulation of protein 
expression and activity as well as the regulation of mRNA transcription. Page et al. 
have shown that HIF-1α expression is increased by angiotensin II via 
diacylglycerol-sensitive protein kinase C-dependent transcriptional regulation in 
addition to the ROS-phosphatidylinositol 3-kinase pathway-dependent translational 
pathway46. A recent study has shown that mice deficient in iron-regulatory protein 1 
exhibit HIF-2α protein accumulation due to de-repression of HIF-2α mRNA and 
induce renal EPO expression47. However, inconsistent with the above results, we have 
/HepG2 cells, indicating that iron negatively regulates HIF-2α expression at the 
transcriptional level in this study. Moreover, SFO-induced HIF-2α mRNA down 
regulation was not changed by tempol treatment, even though SFO-mediated HIF-2α 
protein down regulation was reversed. This suggests that iron transcriptionally 
regulates HIF-2α expression independent of iron-mediated oxidative stress, in addition 
to the post-transcriptional regulation of protein degradation and the DNA binding 
activities of HIF-2α. Further studies are necessary to clarify the mechanism of iron 
regulation on HIF-2α activation.   
Recent studies demonstrate that renal EPO production cells are derived from 
fibroblasts, and the transition of fibroblast to myofibroblast is the main cause of renal 
fibrosis28 and loss of EPO production in CKD16, 17. We previously reported that the 
UUO-induced increase of α-SMA expression in the interstitium was reduced by iron 
chelation15. This indicates that iron participates in the myofibroblast transition during 
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the process of renal fibrosis. Here, we also found that PDGF-Rβ (a fibroblast marker) 
and α-SMA (a myofibroblast marker) expression were enhanced, and that PDGF-Rβ 
and α-SMA were colocalized in the tubulointerstitium in kidneys with SFO treatment. 
These findings suggest that iron promotes renal fibrotic change with transition of 
fibroblasts to myofibroblasts, in part leading to an iron-induced reduction of EPO 
expression. In contrast, superoxide, as well as ferrous iron, was not observed in the 
renal tubulo-interstitium. Therefore, further studies are required to clarify the 
interaction between fibroblast, oxidative stress, and iron in the kidney. 
In the present study, SFO-treated mice showed the reduced plasma EPO 
concentration and the lower level of RBC, Hb and Ht compared to vehicle-treated 
mice, suggesting the decrease of erythropoiesis due to iron-induced reduction of EPO 
production. On the other hand, WBC counts were elevated by SFO treatment.  
Intravenous iron treatment induces protein oxidation, which positively correlates to 
CRP levels in hemodialysis patients48, indicating the association between iron-induced 
oxidative stress and inflammation. Therefore, iron treatment maybe causes 
inflammation as well as oxidative stress, resulting in the increased number of WBC.  
In regard to mice model of UUO, HIF-1α mRNA was not changed and 
HIF-1α protein was diminished in UUO kidney at day 7 after surgery in our study.  
Souma et al. demonstrate that HIF-1α mRNA was increased in UUO kidney at day 2 
after surgery 17.  This discrepancy of HIF-1α expression might be responsible for the 
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different sampling point after UUO induction or the discordance of protein and mRNA 
expression.   
In conclusion, parenteral iron supplementation reduced EPO gene expression 
via oxidative stress-induced HIF-2α inactivation. These findings suggest a new 
potential risk of parenteral iron supplementation and a causative role of therapeutic 
excess iron in the further deterioration of endogenous erythropoietin production in 
CKD. 
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Figure legends 
Figure 1. Expression of erythropoietin (EPO) and hypoxia-inducible factors (HIFs) in 
kidneys with unilateral ureteral obstruction (UUO) and iron treatment. (A) Changes in 
EPO mRNA expression from kidney of sham-operated or UUO mice at day 7. 
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Quantitative real-time reverse transcriptase-polymerase chain reaction (qRT-PCR) 
analysis of EPO mRNA expression. Values are expressed as means ± SD. **P < 0.01 
vs. sham-operation. n = 12 in each group. (B) qRT-PCR analysis of HIF-2α and 
HIF-1α mRNA expression. Values are expressed as means ± SD. **P < 0.01 vs. 
sham-operation. n = 12 in each group. (C) Right panels; representative figures of 
HIF-2α and HIF-1α from kidney at 7 days after sham-operation or UUO. Left panel: 
semi-quantitative analysis of densitometry for HIF-2α and HIF-1α expression. Values 
are expressed as means ± SD. *P < 0.05, **P < 0.01 vs. sham operation. n = 3 in each 
group. (D) Changes in EPO mRNA expression from kidney of vehicle- or SFO-treated 
UUO mice. qRT-PCR analysis of EPO mRNA expression. Values are expressed as 
means ± SD. **P < 0.01 vs. vehicle. n = 11-13. (E) qRT-PCR analysis of HIF-2α and 
HIF-1α mRNA expression. Values are expressed as means ± SD. **P < 0.01 vs. 
sham-operation. n = 11–13 in each group. (F) Left panels; representative figures of 
HIF-2α and HIF-1α from kidney with vehicle- or iron-treatment. Right panel: 
semi-quantitative analysis of densitometry for HIF-2α and HIF-1α expression. Values 
are expressed as means ± SD. **P < 0.01 vs. sham operation. n = 12 in each group. 
Figure 2. (A) Representative hematoxylin and eosin staining of the kidney section. (B) 
Western blot analysis showing induced effects of iron on PDGF-Rβ and α-SMA 
expression in kidney. Upper panels; representative figures of PDGF-Rβ from kidney 
with vehicle- or SFO-treatment. Lower panel: Semi-quantitative analysis of 
densitometry for PDGF-Rβ expression. Values are expressed as means ± SD. *P < 
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0.05 vs. sham operation. n = 8 in each group. (C) Upper panels; representative figures 
of α-SMA from the kidney with vehicle- or SFO-treatment. Lower panel: 
semi-quantitative analysis of densitometry for α-SMA expression. Values are 
expressed as means ± SD. **P < 0.01 vs. sham operation. n = 4 in each group. (D) 
Iron-induced transition from fibroblast to myofibroblast in kidney. Representative 
immunohistochemistry of DAPI (blue), PDGF-Rβ (green), and α-SMA (red) staining. 
(E) SFO-increased labile ferrous iron in the kidney. Left panels; representative figures 
of RhoNox-1staining in the kidney with or without SFO treatment. Right panel: 
semi-quantitative analysis of fluorescence intensity. Values are expressed as means ± 
SD. *P < 0.05 vs. vehicle treatment. n = 4 in each group. (F) Iron-induced oxidative 
stress production in the kidney. Left panels; representative figures of dihydroethidium 
(DHE) staining in kidney with or without SFO treatment. Right panel: 
semi-quantitative analysis of fluorescence intensity. Values are expressed as means ± 
SD. **P < 0.01 vs. vehicle treatment. n = 3 in each group. (G) Fluorescence and light 
microscope images of DHE staining, and merged image of the same field of the kidney 
section. G: glomeruli. (H) Fluorescence image of lectin (green), E-cadherin (blue), 
RhoNOX-1 (red), and merged image of the same field of the kidney section. 
Figure 3. The effect of iron on EPO and HIFs expression in HepG2 cells. (A) HepG2 
cell viability was significantly decreased only by 1000 µg/ml SFO treatment. Values 
are expressed as means ± SD. **P < 0.01 vs. vehicle treatment. n = 8 in each group. 
(B) Impact of SFO on EPO mRNA expression and dose-dependency in HepG2 cells. 
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Values are expressed as means ± SD. **P < 0.01 vs. vehicle treatment. n = 4 in each 
group. SFO action on HIFs expression in HepG2 cells. (C) Quantitative analysis of for 
HIF-2α and HIF-1α mRNA expression. Values are expressed as means ± SD. *P < 
0.05 vs. vehicle treatment. n = 6 (D) Upper panels; representative figures of HIF-2α, 
HIF-1α protein and tubulin with vehicle- or SFO treatment. Lower panel: 
semi-quantitative analysis of densitometry for HIF-2α protein expression. Values are 
expressed as means ± SD. *P < 0.05, **P < 0.01 vs. vehicle treatment. n = 6 in each 
group. (E) Impact of SFO on cobalt chloride-induced EPO, HIF-2α and HIF-1α 
expression in HepG2 cells. Suppressive effect of SFO on cobalt chloride-induced EPO 
mRNA upregulation in HepG2 cells. Values are expressed as means ± SD. *P < 0.05, 
**P < 0.01 vs. vehicle treatment. n = 8 in each group. (F) SFO suppressive action on 
cobalt chloride-induced upregulation of HIF-2α and HIF-1α expression in HepG2 cells. 
Upper panels; representative figures of HIF-2α and tubulin. Lower panel: 
semi-quantitative analysis of densitometry for HIF-2α expression. Values are expressed 
as means ± SD. *P < 0.05, **P < 0.01 vs. vehicle treatment. n = 9 in each group. Effect 
of SFO on DMOG-induced EPO, HIF-2α, and HIF-1α expression in HepG2 cells. (G) 
Inhibitive effect of SFO on DMOG-induced EPO mRNA upregulation in HepG2 cells. 
Values are expressed as means ± SD. *P < 0.05 vs. vehicle treatment. n = 4 in each 
group. (H) SFO inhibitive effect on DMOG-induced upregulation of HIF-2α and 
HIF-1α expression in HepG2 cells. Upper panels; representative figures of HIF-2α and 
tubulin. Lower panel: semi-quantitative analysis of densitometry for HIF-2α 
 29 
 
expression. Values are expressed as means ± SD. *P < 0.05, **P < 0.01 vs. vehicle 
treatment. n = 8 in each group.  
Figure 4. Involvement of oxidative stress in iron-induced down-regulation of EPO and 
HIFs expression in HepG2 cells. (A) Upper panels; representative figures of RhoNox-1 
staining in HepG2 cells with or without SFO. Lower panel: quantitative analysis of 
fluorescence intensity measured by microplate reader. Values are expressed as means ± 
SD. **P < 0.01 vs. vehicle treatment. n = 8 in each group. (B) Upper panels; 
representative figures of DCFH-DA staining in HepG2 cells with or without SFO. 
Lower panel: quantitative analysis of fluorescence intensity measured by microplate 
reader. Values are expressed as means ± SD. *P < 0.05 vs. vehicle treatment. n = 16 in 
each group. (C) Effect of anti-oxidant agent on SFO-induced oxidative stress. 
Quantitative analysis of DCFH-DA fluorescence intensity measured by microplate 
reader. Values are expressed as means ± SD. **P < 0.01. n = 16 in each group. (D) 
Restorative effect of tempol on SFO-induced EPO mRNA down-regulation in HepG2 
cells. Values are expressed as means ± SD. *P < 0.05, **P < 0.01 vs. vehicle 
treatment. n = 8 in each group. (E) Tempol has effect on SFO-induced HIF-2α mRNA 
down-regulation in HepG2 cells. Values are expressed as means ± SD. **P < 0.01 vs. 
vehicle treatment. n = 8 in each group. (F) Restorative effect of tempol on iron-induced 
down-regulation of HIF-2α and HIF-1α expression in HepG2 cells. Values are 
expressed as means ± SD. *P < 0.05 vs. vehicle treatment. n = 6 in each group. (G) 
ChIP analysis of HIF-2α protein and the Epo HRE containing promoter interaction in 
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HepG2 cells. Co-precipitated DNA fragments were detected by PCR using primers 
spanning the EPO HRE region. (H) SFO suppressed hypoxia-responsive element 
(HRE)-luciferase activity in HepG2 cells. Values are expressed as means ± SD. *P < 
0.05 vs. vehicle treatment. n = 6 in each group.  
Figure 5. (A) Changes in VEGF, PHD3, and PGK1 mRNA expression in the kidney of 
vehicle- or SFO-treated mice. Values are expressed as means ± SD. *P < 0.05, **P < 
0.01 vs. vehicle. n = 11–13 in each group. (B) The effect of SFO on VEGF, PHD3, and 
PGK1 mRNA expression in HepG2 cells. Values are expressed as means ± SD. *P < 
0.05 vs. vehicle. n = 4 in each group. Effects of SFO on (C) EPO and (D) HIFs in mice 
with phlebotomy-induced anemia. Values are expressed as means ± SD. *P < 0.05, 
**P < 0.01 vs. vehicle. n = 7 in each group.  
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Table 1 Sequence of the primers for Real-time PCR  














































Table.2 Hematological characteristics 
 RBC (×104/µl) Hb (g/dl) Ht (%) WBC (/µl) Platelet (×104/µl) 
Vehicle 870 ± 50 13.2 ± 0.9 40.7 ± 2.2 4575 ± 340 58.4 ± 3.2 
SFO 828 ± 54 12.6 ± 0.9 38.9 ± 2.7 7623 ± 684** 45.6 ± 7.9* 
Data are means ± SD; n=4, respectively. * P < 0.05, **P < 0.01 vs vehicle-treated mice
Table.3 Hematological characteristics 
 RBC (×104/µl) Hb (g/dl) Ht (%) WBC (/µl) Platelet (×104/µl) 
Control 897 ± 39 13.6 ± 0.6 40.7 ± 1.7 4367 ± 2084 54.1 ± 3.1 
Phlebotomy 469 ± 87** 7.4 ± 1.3** 22.4 ± 3.6** 3766 ± 1666 54.1 ± 14.7 
Phlebotomy+SFO 432 ± 14** 6.7 ± 0.4** 20.5 ± 0.3** 4600 ± 985 31.1 ± 19.2 
Data are means ± SD; n=3, respectively. **P < 0.01 vs control mice
Table 4. Plasma EPO concentration 
 Vehicle SFO 
Plasma EPO (pg/ml) 151.5 ± 44.4 103.9 ± 39.4* 
Data are means ± SD; n=8-12, respectively. *P < 0.05 vs vehicle-treated mice 
 
 Control Phlebotomy Phlebotomy +SFO 
Plasma EPO (pg/ml) 148.3 ± 64.8 10731.7 ± 2366.5** 8087.5 ± 2061.3**# 
Data are means ± SD; n=7, respectively. **P < 0.01 vs control mice, #P < 0.05 vs phlebotomy mice 
 
 
 
 






